COMPARATIVE ASSAY OF CIPROFLOXACIN AND DOXYCYCLINE BRANDS MARKETED IN PORT HARCOURT METROPOLIS NIGERIA AGAINST Staphylococcus aureus CLINICAL ISOLATE
Hanson Ige Ogbu* and Ikhogenehata Precious Momodu
Staphylococcus aureus is among the most prominent causes of bacterial infections and because of its unique nature, it can quickly respond to new antibiotic with the development of efficient mechanisms to neutralize them. Undoubtedly, this has left fewer effective drugs to treat these often-life-threatening infections. The aim of this study was to evaluate the potency of ciprofloxacin and doxycycline brands marketed within Port Harcourt Metropolis against Staphylococcus aureus clinical isolate obtained from the Department of Microbiology University of Port Harcourt Teaching Hospital, Nigeria. The minimum inhibitory, sub inhibitory and bactericidal concentrations (MIC, MBC) of the test antibiotics were determined using standard methods. The MIC range for ciprofloxacin was 0.01953125 - 0.065104166 mg/ml, Â½ Ã— MIC, 0.009765625 - 0.032552066 mg/ml, 2 Ã— MIC, 0.0390625 - 0.130208333 mg/ml and MBC 0.625-2.5 mg/ml. The MIC results for doxycycline ranged from 0.000325521 - 0.026041666 mg/ml, Â½ Ã— MIC 0.00016276 - 0.013020833 mg/ml, 2 Ã— MIC 0.000651042 - 0.05208333 and MBC 0.078125 - 0.3125 mg/ml. In this study, sensitivity and effectiveness of doxycycline is higher than that of ciprofloxacin. The different brands showed variation in their sensitivity and effectiveness against the test microorganism. This disparity may be attributed to several factors including pharmacological variability between drug batches or between generic and originator drugs, incorrect drug quantity and presence of impurities, acquisition of resistance through mutations in some of their genes when they are exposed to an antibiotic. A concerted effort is required to ensure that only medicines of acceptable quality reach the end user.
Keywords: Staphylococcus aureus, minimum inhibitory concentration, minimum bactericidal concentration, ciprofloxacin, doxycycline, brands, sensitivity.
[Full Text Article]